ProQR Therapeutics (PRQR) Long-Term Deferred Tax (2024 - 2025)

ProQR Therapeutics has reported Long-Term Deferred Tax for 4 years, with the latest figure at $3.3 million in Q4 2025.

• Quarterly Long-Term Deferred Tax fell 4.37% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (down 4.37% YoY) and the FY2025 annual result came in at $3.3 million, down 4.37% from the prior year.
• Long-Term Deferred Tax eased to $3.3 million in Q4 2025 per PRQR's latest filing, from $3.5 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $4.3 million in Q4 2023 and troughed at $3.3 million in Q4 2025.
• A 4-year average of $3.8 million and a median of $3.7 million in 2022 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax climbed 7.13% in 2023, then slipped 18.73% in 2024.
• Over 4 years, Long-Term Deferred Tax stood at $4.0 million in 2022, then climbed by 7.13% to $4.3 million in 2023, then dropped by 18.73% to $3.5 million in 2024, then decreased by 4.37% to $3.3 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.3 million, $3.5 million, and $4.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.